OCT 2 4 2005

SCHERING-PLOUGH CORPORATION

LAW DEPARTMENT

2000 GALLOPING HILL ROAD

K-6-1, MAIL STOP 1990

KENILWORTH, NEW JERSEY 07033

(908) 298-4000

FACSIMILE TRANSMITTAL SHEET

TO:
Examiner: E. Bembardt
USPTO

PHONE NUMBER:

Plaiyur S. Kalyanaraman

Palaiyur S. Kalyanaraman

(908) 298-5068

TOTAL NO. OF PAGES INCLUDING COVER

13

October 24, 2005

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Ashly Armstrong at (908) 298-4025.

NOTES/COMMENTS:

PLEASE HAND DELIVER

In re Application of: K. Paruch et al.

For Patent entitled: "17-β-Hydroxysteroid Dehydrogenasc Type 3 Inhibitors for the

Treatment of Androgen Dependent Diseases"

Group Art Unit: 1624 Filed: 11/14/2003

Attorney Docket No.: OC01574

Serial No.: 10/713,828

Dear Examiner Bernhardt,

Transmitted herewith are:

- > Fax Cover Sheet 1pg.
- Certificate of Transmission 1pg.
- Response Transmittal 1pg.
- Amendment 10 pages

Palaiyur S. Kalyanaraman Registered Representative Registration No. 34,634 Docket Number:

OC01574

Application No:

10/713,828

Filing Date:

11/14/2003

First Inventor:

PARUCH, Kamil

PTO/SB/97 (08-04)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARYMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office at (571) 273-8300

| วก | 10/24/2005 | |
|----|------------|---|
| | Date | |
| | | Pm |
| _ | | F81/2 |
| | | Signature |
| _ | | PALAIYUR S. KALYANARAMAN |
| _ | | Typed or printed name of person signing Certificate |
| | | · |

34,634 Registration Number, if applicable

908-298-5068 Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Fax Cover Sheet - 1pg. Certificate of Transmission - 1pg. Amendment - 10pgs.

This collection of information is required by 37 CFR 1.8. The information is required to obtain or rotain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and automitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, chould be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX CENTER

OCT 2 4 2005

| Express Mail Label: PTO/SB/21 (09-04) AD0/0ved for use through 07/31/2006 ORM 0851 095 | | | | | | | | | | |
|---|---|--------|---|---|--------------------|--|-------------------------------|--|--|--|
| Approved for use through 07/31/2006. OMB 0651 U.S. Patent end Trademark Office; U.S. DEPARTMENT OF COMME Under the Passwork Reduction Act of 1995, no persons are required to respond to a collection of information values it displays a valid OMB control nut | | | | | | | | | | |
| | | | | Application Number | | 10/713.828 | | | | |
| TRANSMITTAL | | | | Filing Date | | 11/14/2003 | | | | |
| FORM | | | | First Named Inventor | | PARUCH, Kamil | | | | |
| , 514 | | | Art Unit | | 1624 | | | | | |
| | | | | Examiner Name | | E. Bernhardt | | | | |
| (to be used for all correspondence after initial filling) | | | Altomey Docket Number | | | | | | | |
| Total Number of Pages in This Submission 13 | | | | , montey bocket Humber | occ | OC01574 | | | | |
| ENCLOSURES (Check all that apply) | | | | | | | | | | |
| Fee Trans | smiltal F | orm | | Drawing(s) | | After | Allowance Communication to TC | | | |
| F | Fee Attached | | | Journal Papers | | Appeal Communication to Board of Appeals and Interferences | | | | |
| Amendment/Reply | | | Petition | Appeal Communication to TC (Appeal Notice, Brief, Reply Brief | | al Communication to TC al Notice, Brief, Reply Brief) | | | | |
| After Final | | | Petition to Convert to a Provisional Application | | | ietary Information | | | | |
| | | | Power of Attorney, Revocation Change of Correspondence Address | | Statu | s Letter | | | | |
| | | | Terminal Disclaimer | a r 1041 433 | X Other | Enclosure(s) (please Identify | | | | |
| | | | | | Request for Refund | | Fax Cover Sheet - 1pg. | | | |
| | | | | • | | Eavic | | | | |
| Informatio | Information Disclosure Statement | | | D. Number of CD(s) | | | of Transmission - 1pg. | | | |
| | · L | | | Landscape Table on CD | | | Tog. | | | |
| | Certified Copy of Priority Remark Document(s) | | | | | | | | | |
| Reply to N | vissing F | Parts/ | | | | | | | | |
| incomplet | | | | | | | | | | |
| Reply to Missing Parts under 37 CFR 1.52 or 1.53 | | | | | | | | | | |
| | | | | | • | | | | | |
| | | SIGNA | TURE O | F APPLICANT, ATT | ORNEY, C | R AGENT | | | | |
| Firm Name Customer No: 24265 | | | | | | | | | | |
| Signature | | 200 | 780 | | | | | | | |
| Printed name PALAIYUR S. KALYANARA | | MAN | | | | | | | | |
| Date | 10/24 | 2005 | | | Reg. No. 34,634 | | | | | |
| | | | | | | | | | | |
| CERTIFICATE OF TRANSMISSION/MAILING | | | | | | | | | | |
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria. VA 22313-1450 on the date shown below: | | | | | | | | | | |
| Signature | | | | | | | | | | |
| Typed or printed name | | | | ! | | | | | | |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX CENTER

OCT 2 4 2005

PATENT: 0C01574

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

K. Paruch et al.

Examiner: E. Bernhardt

Serial No.: 10/713,828

Group Art Unit: 1624

Filed: November 14, 2003

For: "17-β-Hydroxysteroid Dehydrogenase : Type 3 Inhibitors For The Treatment of : Androgen Dependent Diseases"

Mailstop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT

Sir:

This amendment is in response to the Official Action dated October 12, 2005, on the above-identified patent application. This communication is being faxed to 571-273-8300 to the Examiner's attention.

Applicants respectfully request entry of the following Amendment.

Amendment to the Specification begins on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 8 of this paper.